Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Long-Term Deferred Tax: 2010-2025

Historic Long-Term Deferred Tax for Anika Therapeutics (ANIK) over the last 3 years, with Sep 2025 value amounting to $1.3 million.

  • Anika Therapeutics' Long-Term Deferred Tax fell 15.01% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year decrease of 15.01%. This contributed to the annual value of $1.2 million for FY2024, which is 20.95% down from last year.
  • Anika Therapeutics' Long-Term Deferred Tax amounted to $1.3 million in Q3 2025, which was down 0.24% from $1.3 million recorded in Q2 2025.
  • Over the past 5 years, Anika Therapeutics' Long-Term Deferred Tax peaked at $1.5 million during Q1 2023, and registered a low of $1.2 million during Q4 2024.
  • Its 3-year average for Long-Term Deferred Tax is $1.4 million, with a median of $1.4 million in 2024.
  • Within the past 5 years, the most significant YoY rise in Anika Therapeutics' Long-Term Deferred Tax was 3.37% (2024), while the steepest drop was 20.95% (2024).
  • Anika Therapeutics' Long-Term Deferred Tax (Quarterly) stood at $1.4 million in 2022, then increased by 2.76% to $1.5 million in 2023, then fell by 20.95% to $1.2 million in 2024, then decreased by 15.01% to $1.3 million in 2025.
  • Its last three reported values are $1.3 million in Q3 2025, $1.3 million for Q2 2025, and $1.2 million during Q1 2025.